CN110974821A - Eurycomanone及其类似物在制备治疗高脂血症、脂肪肝药物或减肥产品的用途 - Google Patents
Eurycomanone及其类似物在制备治疗高脂血症、脂肪肝药物或减肥产品的用途 Download PDFInfo
- Publication number
- CN110974821A CN110974821A CN201911348308.4A CN201911348308A CN110974821A CN 110974821 A CN110974821 A CN 110974821A CN 201911348308 A CN201911348308 A CN 201911348308A CN 110974821 A CN110974821 A CN 110974821A
- Authority
- CN
- China
- Prior art keywords
- eurycomanone
- analogues
- fatty liver
- solution
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UCUWZJWAQQRCOR-OKNZMGBLSA-N eurycomanone Chemical compound O1C(=O)[C@H](O)[C@@]2(O)C(=C)[C@@H](O)[C@@]3(O)[C@@H]4[C@@]5(C)[C@H](O)C(=O)C=C(C)[C@@H]5C[C@@H]1[C@]42CO3 UCUWZJWAQQRCOR-OKNZMGBLSA-N 0.000 title claims abstract description 79
- UCUWZJWAQQRCOR-UHFFFAOYSA-N Pasakbumin A Natural products O1C(=O)C(O)C2(O)C(=C)C(O)C3(O)C4C5(C)C(O)C(=O)C=C(C)C5CC1C42CO3 UCUWZJWAQQRCOR-UHFFFAOYSA-N 0.000 title claims abstract description 72
- 239000009947 eurycomanone Substances 0.000 title claims abstract description 72
- 239000003814 drug Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 208000004930 Fatty Liver Diseases 0.000 title claims abstract description 16
- 206010019708 Hepatic steatosis Diseases 0.000 title claims abstract description 16
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 16
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 16
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims abstract description 16
- 229940079593 drug Drugs 0.000 title claims abstract description 15
- 239000000243 solution Substances 0.000 claims description 50
- 150000001875 compounds Chemical class 0.000 claims description 9
- -1 Eurycomanone compound Chemical class 0.000 claims description 7
- 150000002772 monosaccharides Chemical group 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 201000005577 familial hyperlipidemia Diseases 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 2
- 238000009098 adjuvant therapy Methods 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 208000016261 weight loss Diseases 0.000 claims 3
- 230000004580 weight loss Effects 0.000 claims 3
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 claims 1
- 230000004069 differentiation Effects 0.000 abstract description 41
- 210000001789 adipocyte Anatomy 0.000 abstract description 27
- 210000000229 preadipocyte Anatomy 0.000 abstract description 11
- 208000008589 Obesity Diseases 0.000 abstract description 10
- 235000020824 obesity Nutrition 0.000 abstract description 10
- 210000004185 liver Anatomy 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 230000004130 lipolysis Effects 0.000 abstract description 5
- 210000002966 serum Anatomy 0.000 abstract description 5
- 230000004936 stimulating effect Effects 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 44
- 239000012224 working solution Substances 0.000 description 40
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 32
- 102000004877 Insulin Human genes 0.000 description 22
- 108090001061 Insulin Proteins 0.000 description 22
- 229940125396 insulin Drugs 0.000 description 22
- 239000001963 growth medium Substances 0.000 description 18
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 17
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 17
- 229960003957 dexamethasone Drugs 0.000 description 17
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 15
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 238000012258 culturing Methods 0.000 description 12
- 238000010186 staining Methods 0.000 description 9
- 238000009825 accumulation Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 101100387135 Caenorhabditis elegans dex-1 gene Proteins 0.000 description 5
- 230000001603 reducing effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 240000005739 Eurycoma longifolia Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 230000024245 cell differentiation Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 229910021642 ultra pure water Inorganic materials 0.000 description 4
- 239000012498 ultrapure water Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000016267 Leptin Human genes 0.000 description 3
- 108010092277 Leptin Proteins 0.000 description 3
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 3
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000019280 Pancreatic lipases Human genes 0.000 description 3
- 108050006759 Pancreatic lipases Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 229940039781 leptin Drugs 0.000 description 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 3
- 229940116369 pancreatic lipase Drugs 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 101800001982 Cholecystokinin Proteins 0.000 description 2
- 102100025841 Cholecystokinin Human genes 0.000 description 2
- IROWCYIEJAOFOW-UHFFFAOYSA-N DL-Isoprenaline hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(O)C(O)=C1 IROWCYIEJAOFOW-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 2
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- 238000013218 HFD mouse model Methods 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101001129187 Homo sapiens Patatin-like phospholipase domain-containing protein 2 Proteins 0.000 description 2
- 102400001132 Melanin-concentrating hormone Human genes 0.000 description 2
- 101800002739 Melanin-concentrating hormone Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 102100031248 Patatin-like phospholipase domain-containing protein 2 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 235000021407 appetite control Nutrition 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940107137 cholecystokinin Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229940018448 isoproterenol hydrochloride Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229940043437 protein kinase A inhibitor Drugs 0.000 description 2
- 239000012656 protein kinase A inhibitor Substances 0.000 description 2
- 108010065251 protein kinase modulator Proteins 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000036186 satiety Effects 0.000 description 2
- 235000019627 satiety Nutrition 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 210000000636 white adipocyte Anatomy 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- NOOYIVIUEHDMSF-PKLMIRHRSA-N (2r)-1-phenyl-n-(3-phenylpropyl)propan-2-amine;hydrochloride Chemical compound Cl.C([C@@H](C)NCCCC=1C=CC=CC=1)C1=CC=CC=C1 NOOYIVIUEHDMSF-PKLMIRHRSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 101710168309 CCAAT/enhancer-binding protein alpha Proteins 0.000 description 1
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 206010057672 Male sexual dysfunction Diseases 0.000 description 1
- 108010008364 Melanocortins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000020369 Polymerase proofreading-related adenomatous polyposis Diseases 0.000 description 1
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Natural products CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001593 brown adipocyte Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002865 melanocortin Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011555 saturated liquid Substances 0.000 description 1
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 229940094720 viagra Drugs 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明属医药生物技术领域,涉及Eurycomanone及其类似物在制备治疗高脂血症、脂肪肝药物或减肥产品的用途,所述的治疗高脂血症、脂肪肝和减肥药物、保健食品中含有的Eurycomanone及其类似物是单体化合物或任意多种化合物的混合物。Eurycomanone及其类似物通过抑制前脂肪细胞分化和刺激脂肪细胞的脂肪分解,能够降低血清中TG水平,减小脂肪细胞体积,减少肝内LDs数量,从而发挥治疗和预防高脂血症、脂肪肝和肥胖的作用。
Description
技术领域
本发明属于生物医药和食品领域,具体涉及Eurycomanone及其类似物制备成药物用于高脂血症、脂肪肝和肥胖症的治疗,或制成保健食品用于肥胖和高脂血症的预防。
背景技术
随着现代社会的发展,人们生活水平的提高,心脑血管疾病是老年人常见疾病,不仅具有很高的致残率,而且如果不及时治疗则会威胁患者的生命。据统计,全世界每年因心脑血管疾病而死亡的人数高达1500万人,在各类疾病中的病死率居于首位,而肥胖是导致糖尿病、心脑血管疾病的重要原因,因此肥胖已经成为大家关注的热点之一。
对于导致肥胖的原因,总的来说就是能量的摄入超过人能量的消化,使过多的能量以脂肪的形势储存在人体内。
目前治疗肥胖的机理有三种,分别是:
调节脂质吸收:脂肪中包含90%的甘油三酯(TG),甘油三酯在胰脂酶(pancreaticlipase) 的作用下水解成甘油一酸酯(MG)和脂肪酸(FA),然后与胆汁酸(bileacids)、溶血磷脂酸(LPA) 以及胆固醇(Cholesterol)共同形成混合胶束被肠细胞吸收并再合成为甘油三酯储存在白色脂肪细胞(WAT)中,不断地积累最终导致肥胖产生。奥利司作为胰脂酶抑制剂,通过抑制胰脂酶的活性进而使食物中的甘油三脂不会被分解为单糖和脂肪酸,而是直接排出体外。
能量消耗:前体脂肪细胞通过增殖分化成白色脂肪细胞(WAT)和褐色脂肪细胞(BAT),白色脂肪细胞的增殖增大进而导致脂肪代谢紊乱,血浆中游离脂肪酸水平上升,进而再合成为脂肪,过量的脂肪积累导致肥胖发生。活性成分抑制脂肪前体细胞的增殖分化,那么在增殖分化过程中的PPARY和C/EBPα减少,进而可以抑制白色脂肪细胞的增殖肥大,就不会导致脂肪的合成达到减肥效果;或者通过促进生成BAT,使BAT与浅褐色脂肪细胞当中的 UCP1(解偶联蛋白1)上升,UCP1水平上升进而生热使能量消耗进而达到减肥效果。
食欲相关激素调节:通过激活下丘脑中厌食多肽和抑制食欲的多肽,可以抑制神经肽 Y(NPY),黑色素浓集激素(MCH),刺鼠色蛋白相关蛋白(AgRP)使饱腹感上升而减少食物摄入达到减肥效果,激活厌食的激素可卡因-苯丙胺调节转录(CART),前黑皮素原(POMC),多巴胺(DA),去加肾上腺素(NE),5-羟色胺(5-HT)z减少食物摄入达到减肥效果;或者通过促进肠中CCK(缩胆囊素)、GLP-1(胰高血糖样肽1)、PYY(多肽YY)进而使胰岛产生胰岛素作用于下丘脑控制食欲;或者抑制胃中Ghrelin(饥饿素)的产生来控制食欲。此外,还可以通过激素或者生长因子间接的调节食欲,比如瘦素就是一个可以通过影响食欲进而调节食物摄入量进而治疗肥胖的一个技术,在正常情况下,瘦素是在动物体需要能量时使机体产生饥饿感,在动物体不需要能量时使机体产生饱腹感,但是病理情况下,瘦素水平与体重成正相关。
东革阿里(Eurycoma longifolia Jack)又名天然伟哥,在马来西亚与燕窝、锡器并称三大国宝,主要分布于马来西亚、泰国等东南亚国家,靠近赤道原始雨林。在东南亚,人们将东革阿里作为药品和补品服用,在作为单味药或作为其他药方中的配药时,东革阿里常常全株入药或根部入药。研究表明其具有抗癌、抗疟疾、改善男性性功能障碍等功效,还可改善身体功能、抗焦虑、抗骨质疏松、抗细菌、抗寄生虫、调节免疫功能、缓解疼痛与炎症、治疗 2型糖尿病和抗血管生成。苦木素二萜类化合物是东哥阿里中主要的一类成分,并且是东革阿里最主要的生物活性成分,Eurycomanone是其中最具代表性的一种。发明人研究发现 Eurycomanone及其类似物具有良好的降脂作用。
发明内容
本发明目的是提供Eurycomanone及其类似物在制备治疗高脂血症、脂肪肝药物或减肥产品的用途。
本发明采用以下技术方案实现:
Eurycomanone及其类似物在制备治疗高脂血症、脂肪肝药物或减肥产品中的用途,所述的Eurycomanone(CAS编号:84633-29-4)的化合物结构如式(1)所示
Eurycomanone的一种类似物化合物结构如式(2)所示
其中,R1为羟基、甲氧基、乙氧基或单糖基;
Eurycomanone的另一种类似物化合物结构如式(3)
R2为甲基、乙基、羟基、甲氧基或乙氧基。
R3为-H、甲基、乙基、乙酰基或单糖基。
上述技术方案中,优选地,所述的治疗高脂血症、脂肪肝的药物中的Eurycomanone及其类似物,可以是单体化合物单独应用,也可以是任意多种化合物的混合物应用。
优选地,治疗高脂血症、脂肪肝的药物,为由治疗上有效量的Eurycomanone类似物单独或与其他药物配伍与药学上可接受的载体组成,可以为在临床上使用的各种不同剂型的药物,包括胶囊(软胶囊)、颗粒剂(干悬混剂)、片剂(分散片、泡腾片、咀嚼片、口崩片)、溶液剂(糖浆)、丸剂(浓缩丸、滴丸、微丸),或者注射剂型等。
优选地,Eurycomanone及其类似物单独或与其他保健食品可接受的物料组成,在制备辅助治疗高脂血症的保健食品和减肥产品中的应用。
本发明中,所述的Eurycomanone及其类似物可以降低血清中TG水平,减小脂肪细胞,减少肝内LDs数量,具有降血脂、减肥和保护肝脏的作用。Eurycomanone类似物的作用途径为抑制抑制3T3-L1前脂肪细胞分化;促进p-PKA的表达,提高对脂肪的分解。
本发明的有益效果在于:
本发明提供了一种治疗和预防高脂血症、脂肪肝和肥胖症的药物、保健食品的原料或潜药,该药物的作用途径为抑制3T3-L1前脂肪细胞分化;促进p-PKA的表达,提高对脂肪的分解,具有较好的开发潜力。
附图说明
图1对高脂饮食小鼠血脂、脂肪组织及肝脏的影响(****p<0.01,n=6);
图2对脂肪细胞分化的影响(10d)(200ⅹ);
图3对成熟脂肪细胞甘油释放量的影响(*p<0.05;n=3);
图4对脂肪分解相关基因mRNA表达的影响(*p<0.05,***p<0.005,****p<0.001, n=4)。
具体实施方式
为使本发明的上述目的、特征和优点能够更加明显易懂,下面结合实施例进一步说明本发明的技术方案。但是本发明不限于所列出的实施例,还应包括在本发明所要求的权利范围内其他任何公知的改变。
实施例1 Eurycomanone体内降脂作用研究
取健康雄性C57BL/6小鼠24只,12周龄,随机分为4组,每组6只,即正常对照组(0.9%生理盐水,10ml/kg),HFD组(0.9%生理盐水,10ml/kg),Eurycomanone组(5mg/kg,10ml/kg),Eurycomanone组(10mg/kg,10ml/kg)。
动物的喂养条件:清洁通风环境,湿度50±5%,室温22±2℃,光照周期为12小时,水食自取。
小鼠采用高脂饲料(HFD:10%猪油、10%蛋黄、1%胆固醇、0.2%胆酸、78.8%标准饲料)喂养8周,建立高脂动物模型。连续灌胃给药两周,每天1次。两周后,动物禁食24h,眼窝采血,并用试剂盒检测甘油水平。颈椎脱臼法处死小鼠,分离附睾脂肪组织及肝脏,-80℃保存。切除肝脏其他部分、附睾及肾周白色脂肪组织,称重,取部分组织固定于10%福尔马林进行组织病理学检查。用4%多聚甲醛对组织进行固定,过夜。石蜡处理、包埋、切片、标准苏木精/伊红染色。使用倒置显微镜(尼康)观察,结果如图1。与对照组相比,HFD喂养的C57BL/6J小鼠血清TG水平升高。灌胃给药能显著降低HFD小鼠的TG水平,增加血清甘油释放。此外,H&E染色显示,经Eurycomanone处理后,HFD喂养的C57BL/6小鼠脂肪细胞体积减小,肝内LDs数量减少。
实施例2 Eurycomanone抑制3T3-L1前脂肪细胞分化
2.1 DMEM完全培养基的配制
250mL DMEM基础培养基中加入28mL FBS和2.8mL青链霉素,混匀,配成终浓度为10%FBS和1%青链霉素的完全培养基,存于4℃冰箱待用。
2.2 Eurycomanone工作液的配制
Eurycomanone的相对分子质量为408.1,精密取Eurycomanone 16.32mg,加入100μL二甲基亚砜(DMSO),涡旋震荡溶解,0.22μm滤膜过滤,制成400mM工作液,密封,-20℃保存。使用时,用培养基稀释至所需浓度,保证各浓度Eurycomanone液中DMSO的终浓度小于0.1%。
2.3磷酸盐缓冲液(PBS)的配制
将80.0g NaCl,2.0g KCl,18.1g Na2HPO4·2H2O,2.4g KH2PO4溶于800mL双蒸水中;调整pH至7.4,补充双蒸水至1L;灭菌,储存于4℃冰箱。
2.4胰岛素工作液的配制
精密称取10.00mg胰岛素(INS),放置于5mL pH=2的盐酸中溶解,配制浓度成2mg/mL 的工作液液,再通过0.22μm滤膜过滤,于-20℃冰箱保存。
2.5地塞米松工作液的配制
精密称取2.00mg地塞米松(DEX),放置于5mL无水乙醇中溶解,配制浓度为1mg/mL的工作液,通过0.22μm滤膜过滤,于-20℃冰箱保存,临用时1mL培养基加入1μL地塞米松工作液即可。
2.6 3-异丁基-1-甲基黄嘌呤工作液的配制
精密称取6.9mg 3-异丁基-1-甲基黄嘌呤(IBMX),放置于36μL氢氧化钾中溶解,再加入超纯水564μL,置于涡旋仪上,涡旋直至完全溶解,配制浓度为51.7mM的工作液,再通过0.22μm滤膜过滤,于-20℃冰箱保存,培养基中的IBMX终浓度为0.5mM即可。
2.7氢氧化钾(KOH)溶液的配制
精密称取KOH 0.561g,加入10mL超纯水涡旋溶解,成1mol/L KOH溶液。
2.8油红O溶液的配制
准确称取油红O粉末0.05g,先加量异丙醇涡旋溶解,加异丙醇定容到10mL,超声、涡旋、震荡直到有剩余粉末不能溶解为止,得浓度为5mg/mL的油红O饱和液。使用时,按蒸馏水与油红O溶液2:3的比例稀释,混匀,0.22μm无菌滤膜过滤,可使用。
2.9尼罗红工作液的配制
准确称取12.73mg尼罗红,加入200μL DMSO(生物级)溶解,成200mM尼罗红工作液。染色时将工作液用PBS稀释200倍,得1mM的工作液。
2.10诱导分化液A的配制
取1mM地塞米松工作液25μL,51.7mM IBMX工作液240μL、2mg/mL Insulin工作液125μL,混合入50mL离心管中,加入10%FBS DMEM培养液至25mL,即为导分化液A,溶液中分别含DEX 1μM、IBMX 0.5mM、INS 10μg/mL。
2.11诱导分化液B的配制
取2mg/mL Insulin工作液125μL,加入50mL离心管中,加入10%FBS DMEM培养液至25mL,即为导分化液B,溶液中含胰岛素10μg/mL。
2.12 Eurycomanone对成熟脂肪细胞毒性考察
取对数生长期的3T3-L1前脂肪细胞,3-5×105个细胞/孔接种于6孔板中,每两天换一次液。待细胞长满至80%后,接触抑制2d。然后换诱导分化液A(含DEX 1μM、IBMX 0.5mM、INS 10μg/mL的10%FBS DMEM培养液)培养3d,换诱导分化液B(含INS 10μg/mL 的10%FBS DMEM培养液)培养2d后,再换正常培养基继续培养,每两天换一次液,直至细胞分化完成90%以上。
将分化成熟细胞从培养箱中取出,吸弃培养液,加入无血清DMEM培养基配制的0、50、 100、200μM Eurycomanone,培养箱培养24h后,将细胞从培养箱中取出,吸弃培养基,PBS 漂洗两次,加入0.5mL胰蛋白酶/孔后,立即置于培养箱内消化1min,在显微镜下观察细胞消化情况,若细胞回缩变圆、透亮、轻拍瓶壁呈流沙样脱落,则迅速拿回超净台,加入等量完全培养基,终止消化并轻轻吹打细胞,使其变成单细胞悬液,800rpm,5min离心,弃上清,加入无酚红培养基重悬细胞。按照细胞悬液:台盼蓝试剂为9:1的原则,用台盼蓝试剂对细胞染色5min后,取20μL细胞染色液打入计数板中放进细胞计数仪中计数,统计数据,考察结果表明Eurycomanone在0-200μM范围内对成熟脂肪细胞无细胞毒性。
2.13 Eurycomanone抑制细胞分化阶段的考察
取对数生长期的3T3-L1前脂肪细胞,将细胞以浓度为1×106个/孔接种于细胞培养皿中,将皿分组编号为:0、0-2、2-4、4-6、6-8五组,这五组代表加入药物Eurycomanone的时间,此实验用来考察Eurycomanone具体抑制脂肪细胞分化过程的哪个阶段,为后面细胞抑制分化实验打下实验基础。在进行分化之前将上面五组细胞正常培养,每两天换一次液。分化过程中按照不同的分化时间进行加药培养,待细胞长满80%后,接触抑制48h。然后换诱导分化液A(含DEX 1μM、IBMX 0.5mM、INS 10μg/L的10%FBS DMEM培养液)培养48h,加分化液同时加入0、15μM、30μM、45μM Eurycomanone,培养48h,换诱导分化液B(含 INS 10μg/mL的10%FBS DMEM培养液),同时也加入0、15μM、30μM、45μM Eurycomanone 一同培养48h。最后,换基础培养基继续培养,每两天换一次液,再培养四天。最后观察脂肪细胞分化的形态以及脂滴中甘油三酯的累积量。
形态学观察:油红O染色,将分化后的脂肪细胞用适量的PBS洗涤两次,轻轻摇动,清洗后去除PBS,室温下用4%聚甲醛固定2小时,然后用60%异丙醇洗涤两次,在40℃的通风橱或烘箱中干燥,然后加入油红O(用2:3的蒸馏水与油比稀释)并在室温下染色2-3小时或4℃过夜。除去细胞外的油红O,用蒸馏水洗两次,放在倒显微镜下观察拍照。
甘油三酯检测:油红O染色拍照后,将异丙醇加入染色的细胞中,放置摇床上摇2h,每个孔中加入1mL异丙醇萃取出各个给药组分中的油红O。将萃取出的油红O置于96孔板中,每孔加入200μL,在酶标仪中震荡3分钟,于510nm波长处测量吸光度值,实验重复三次。通过这个方法可以间接给每个组分中脂肪滴定量,从而反映Eurycomanone抑制脂肪细胞分化作用。
通过油红O染色可以直观的观察到脂肪细胞的分化形态图。利用异丙醇检测染色后油红 O的含量,以此判定Eurycomanone对3T3-L1成熟脂肪细胞脂肪中甘油三酯累积的影响。结果显示,当加入分化液A时同时加入Eurycomanone作用48h,与对照NC相比,其能有效的抑制甘油三酯的累积,抑制率达11%;当加入分化液B时同时加入Eurycomanone作用48h,与NC对照组相比,能有效的抑制甘油三酯的累积(p<0.05),其抑制率达22%;当加入正常培养基阶段再同时加入Eurycomanone作用,反而还提高了甘油三酯的累积。综合上述结果,得出的结论是Eurycomanone抑制3T3-L1脂肪细胞分化,主要抑制时间是在分化0-4天内,也就是加入分化液A和B分化的时间段。
由此,通过从开始分化起,连续加药四天,然后通过倒置显微镜观察加药抑制细胞分化第10天,油红O染色后的结果,结果如图2。加药组被油红O染色的区域较少,颜色较浅,呈现戒环形的成熟脂肪细胞少于NC组;NC组有大量被染成鲜红色的戒环形脂滴,80%以上的细胞都分化成了呈圆形的脂肪细胞;高浓度给药组被油红O染色的区域是最少的,颜色最浅,呈圆形的细胞也最少,从图中可以明显的看到随着加药浓度的不断提高,细胞分化的水平也逐渐减少。随后,用异丙醇萃取各组染色的油红O,通过酶标仪,在510nm波长处检测吸光度,吸光度可以反映出Eurycomanone对于小鼠3T3-L1前脂肪细胞分化过程中甘油三酯的积累的影响,结果见表1,表明Eurycomanone作用后与NC的结果明显不同,它会造成细胞内甘油三酯积累减少,加药组与正常组相比差异显著(p<0.05)。
表1 Eurycomanone对小鼠3T3-L1前脂肪细胞甘油三酯的积累的影响
实施例3 Eurycomanone促进脂肪分解和机制
3.1 Eurycomanone工作液的配制
精密称取Eurycomanone 8.16mg,加入DMSO(生物级)200μL,配成100mMEurycomanone工作液,于4℃冰箱保存。
3.2盐酸异丙肾上腺素的配制
精密称取盐酸异丙肾上腺素4.95mg,加入DMSO(生物级)200μL,配成100mM异丙肾上腺素工作液,于4℃冰箱保存。
3.3 H-89工作液的配制
精密称取H-89 5.19mg,加入200μL DMSO(生物级),配成终浓度为50mM H-89工作液,于4℃冰箱保存。
3.4培养基的配制
250mL高糖培养基(DMEM,含双抗)中加入28mL FBS,混匀,配成终浓度为10%FBS的完全培养基,存于4℃冰箱待用。
3.5胰岛素工作液的配制
精密称取10.00mg胰岛素(INS),放置于5mL pH=2的盐酸中溶解,配制浓度为2mg/mL 的工作液,再通过0.22μm滤膜过滤,于-20℃冰箱保存。
3.6地塞米松工作液的配制
精密称取2.00mg地塞米松(DEX),放置于5mL无水乙醇中溶解,配制浓度为1mg/mL的工作液,再通过0.22μm滤膜过滤,于-20℃冰箱保存,临用时1mL培养基加入1μL地塞米松工作液即可。
3.7 3-异丁基-1-甲基黄嘌呤工作液的配制
精密称取6.9mg 3-异丁基-1-甲基黄嘌呤(IBMX),放置于36μL氢氧化钾中溶解,再加入超纯水564μL,置于涡旋仪上,涡旋直至完全溶解,配制浓度为51.7mM的工作液,再通过0.22μm滤膜过滤,于-20℃冰箱保存,培养基中的IBMX终浓度为0.5mM即可。
3.8氢氧化钾(KOH)的配制
准确称取KOH 0.561g,加入10mL超纯水溶解,保存于-20℃,临用时用0.22μm滤膜过滤后再使用。
3.9 Q-PCR引物序列
3.10诱导分化液A的配制
取1mM地塞米松工作液25μL,51.7mM IBMX工作液240μL、2mg/mL Insulin工作液125μL,混合入50mL离心管中,加入含10%FBS DMEM培养液至25mL,即为导分化液A,溶液中分别含DEX 1μM、IBMX 0.5mM、INS 10μg/mL。
3.11诱导分化液B的配制
取2mg/mL Insulin工作液125μL,加入50mL离心管中,加入含10%FBS DMEM培养液至25mL,即为导分化液B,溶液含胰岛素10μg/mL。
3.12小鼠3T3-L1前脂肪细胞诱导分化
取对数生长期的3T3-L1前脂肪细胞,3-5×105个细胞/孔接种于6孔板中,每两天换一次液。待细胞长满80%后,接触抑制2d。然后换诱导分化液A(含DEX 1μM、IBMX 0.5mM、INS 10μg/mL的10%FBS DMEM培养液)培养3d,换诱导分化液B(含INS 10μg/mL的 10%FBSDMEM培养液)培养2d后,再换正常培养基继续培养,每两天换一次液,直到细胞分化完成90%以上。
3.13甘油释放药效实验检测
脂肪细胞分化成熟后,我们需要对其进行加药处理,筛选出最佳给药剂量。首先将Eurycomanone工作液用无酚红及含有2%BSA的培养基稀释成梯度浓度组0、10、20、30、 40、50、80、100μM,药物浓度稀释好之后,从恒温培养箱中取出已经分化成熟的脂肪细胞,吸弃培养基,加入新鲜的无FBS高糖培养基(DMEM),再进行血清饥饿处理2-4h,小心吸弃培养基,用PBS小心清洗1-2遍,依次加入配制好的药物,将细胞放回培养箱培养24 h后,用甘油释放试剂盒检测细胞甘油释放量。最后统计甘油释放数据,数据结果显示在0-30 μM甘油释放的量随着Eurycomanone浓度的增加而增加,当给药浓度超过30μM时,甘油释放几乎不变,甚至减少,所以我们可以得出的结论是当给药浓度为30μM左右时, Eurycomanone降脂药效最好。最佳给药浓度左右再确定15、60μM作为最终加药量,用于 Eurycomanone的药效实验,证明Eurycomanone具有好的降脂药效,细胞分化成熟时,收集培养细胞的培养基,甘油测定用于评估Eurycomanone促进脂肪分解的重要指标,脂肪细胞通过Eurycomanone处理持续24h显示出甘油释放显著增加。降脂结果如图3所示,与NC相比,浓度60,30,15μM可以显著促进3T3-L1成熟脂肪细胞甘油释放(p<0.05),甘油释放量分别增加26.77%、35.65%、26.78%。
3.14 Eurycomanone对3T3-L1成熟脂肪细胞中脂肪分解相关酶系及转录因子mRNA表达的影响
实时荧光定量PCR(q-PCR)技术,检测Eurycomanone对3T3-L1成熟脂肪细胞中与脂肪分解相关酶系及转录因子的mRNA表达水平的影响。将30μM Eurycomanone作用于分化成熟的3T3-L1脂肪细胞,作用时间为24h,检测相关基因的表达水平。结果如图4所示,与 NC相比,Eurycomanone可以上调C-AMP的表达水平,但是表达水平未达到显著性水平;Eurycomanone对ATGL的表达无明显影响;Eurycomanone使PKA-CA、PKA-CB的表达量显著上调(p<0.05),其表达水平分别上调70%、71%;Eurycomanone能显著上调HSL、AKT (p<0.001),使其表达水平分别上调56%、139%。使用PKA抑制剂H89用来抑制基因PKA 的表达,然后通过实时荧光定量技术,检测其下游基因以及旁路基因的表达情况,再使用药物Eurycomanone作用于3T3-L1脂肪细胞,结果见图4,当加入PKA抑制剂H89后,PKA-CA 的表达未发生显著性变化;PKA-CB、AKT的表达水平分别下降了71%、51%;当先加入H89 抑制剂2h,再加入药物Eurycomanone共同作用脂肪细胞24h,PKA-CA、PKA-CB、AKT 的表达水平上调,其表达水平分别上调了65%、329%、32%。说明Eurycomanone对涉及ATGL 的这条降脂通路无影响,其降脂活性主要作用于PKA/HSL、AKT/HSL这两条通路。
用Eurycomanone类似物替换Eurycomanone,重复上述实验可得到相似结果。证明Eurycomanone类似物也能够抑制3T3-L1前脂肪细胞分化;促进p-PKA的表达,提高对脂肪的分解,具有较好的降脂活性。
应说明的是,以上实施例仅用以说明本发明的技术方案而非限制,尽管参照较佳实施例对本发明进行了详细说明,本领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者等同替换,而不脱离本发明技术方案的精神和范围,其均应涵盖在本发明的权利要求范围当中。
Claims (4)
2.Eurycomanone及其类似物在制备治疗高脂血症、脂肪肝药物或减肥产品的用途,其特征在于,所述的治疗高脂血症、脂肪肝和减肥产品中含有的Eurycomanone及其类似物是单体化合物或任意多种化合物的混合物。
3.根据权利要求1-2任一项所述的Eurycomanone及其类似物在制备治疗高脂血症、脂肪肝药物或减肥产品的用途,其特征在于,所述的治疗高脂血症、脂肪肝药物是由Eurycomanone及其类似物加工成的胶囊、颗粒剂、片剂、溶液剂、丸剂,或者注射剂型。
4.根据权利要求1-2任一项所述的Eurycomanone及其类似物在制备治疗高脂血症、脂肪肝药物或减肥产品的用途,其特征在于,所述的Eurycomanone及其类似物在制备辅助治疗高脂血症的保健食品或减肥产品中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911348308.4A CN110974821A (zh) | 2019-12-24 | 2019-12-24 | Eurycomanone及其类似物在制备治疗高脂血症、脂肪肝药物或减肥产品的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911348308.4A CN110974821A (zh) | 2019-12-24 | 2019-12-24 | Eurycomanone及其类似物在制备治疗高脂血症、脂肪肝药物或减肥产品的用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110974821A true CN110974821A (zh) | 2020-04-10 |
Family
ID=70074879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911348308.4A Pending CN110974821A (zh) | 2019-12-24 | 2019-12-24 | Eurycomanone及其类似物在制备治疗高脂血症、脂肪肝药物或减肥产品的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110974821A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117965455A (zh) * | 2024-03-28 | 2024-05-03 | 清泽医疗科技(广东)有限公司 | 一种提高car-t细胞功能的组合物及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104415135A (zh) * | 2013-08-29 | 2015-03-18 | 绿茵生技股份有限公司 | 羟基多甲氧基黄酮类化合物及/或其衍生物的用途 |
CN106994131A (zh) * | 2017-04-21 | 2017-08-01 | 中国科学院昆明植物研究所 | 一种调节脂代谢和肥胖的化合物paqg在制药中的应用 |
-
2019
- 2019-12-24 CN CN201911348308.4A patent/CN110974821A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104415135A (zh) * | 2013-08-29 | 2015-03-18 | 绿茵生技股份有限公司 | 羟基多甲氧基黄酮类化合物及/或其衍生物的用途 |
CN106994131A (zh) * | 2017-04-21 | 2017-08-01 | 中国科学院昆明植物研究所 | 一种调节脂代谢和肥胖的化合物paqg在制药中的应用 |
Non-Patent Citations (1)
Title |
---|
D BALAN等: "Antiadipogenic effects of a standardized quassinoids-enriched fraction and eurycomanone from Eurycoma longifolia", 《PHYTOTHERAPY RESEARCH》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117965455A (zh) * | 2024-03-28 | 2024-05-03 | 清泽医疗科技(广东)有限公司 | 一种提高car-t细胞功能的组合物及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101135824B1 (ko) | 잔토세라스 소르비폴리아 추출물을 포함하는 조성물,이로부터 단리된 화합물, 이의 제조방법 및 이의 용도 | |
KR101533600B1 (ko) | 항비만효과를 갖는 장수풍뎅이 유충 추출물의 제조방법 및 이를 포함하는 항비만 조성물 | |
CN110548037B (zh) | 精制熊胆粉及其增强体质治疗和预防肿瘤和癌症的用途 | |
TW200427455A (en) | Water soluble extract from plant of solanum genus and the preparation process thereof, and pharmaceutical composition containing the water soluble extract | |
TWI598104B (zh) | Use of Antrodia cinnamomea extract to improve side effects of chemotherapy | |
WO2021249420A1 (zh) | 血筒素在制备抗类风湿关节炎药物中的应用 | |
KR20110100329A (ko) | 신생혈관형성 억제용 한약 조성물 | |
KR20170005632A (ko) | 뜰보리수 추출물을 포함하는 비만 또는 고지혈증의 예방 또는 치료용 조성물 | |
WO2021223346A1 (zh) | 山药蛋白提取物在制备治疗勃起功能障碍的药物中的应用 | |
CN1460482A (zh) | 一种含淫羊藿素、去甲基淫羊藿素的药物组合物及其用途 | |
CN110974821A (zh) | Eurycomanone及其类似物在制备治疗高脂血症、脂肪肝药物或减肥产品的用途 | |
RU2727142C2 (ru) | Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей | |
CN100349577C (zh) | 黄芩总黄酮提取物及黄芩苷在抗骨质疏松药物制备中的用途 | |
CN109718273A (zh) | 紫苏叶提取物在预防或治疗骨性关节炎中的应用 | |
CN111491645A (zh) | 包含鹿角卷柏提取物、其分馏物的用于预防或治疗代谢综合症的组合物 | |
CN105193795A (zh) | 两种卤酚化合物在促血管生成作用方面的应用 | |
CN110507670B (zh) | 精制熊胆粉及预防治疗肝病肝纤维化改善肝功能的用途 | |
KR20150020001A (ko) | 히드록시기 폴리메톡시플라본 화합물 및 그 유도체를 사용하는 방법 | |
Yu et al. | Kaempferol attenuates wear particle-induced inflammatory osteolysis via JNK and p38-MAPK signaling pathways | |
CN113648306A (zh) | 佛手柑素在预防或治疗骨质疏松和/或骨丢失中的应用 | |
CN111544440A (zh) | 地奥司明及组合物在制备抗肥胖的产品方面中的应用 | |
CN110946986A (zh) | 一种寡肽在制备防治非酒精性脂肪肝病药物中的应用 | |
CN111773180B (zh) | 一种甘露聚糖在诱导骨再生方面的应用 | |
Shao et al. | Flavonoids from Dalbergia cochinchinensis: Impact on osteoclastogenesis | |
CN114949242B (zh) | 含硒化合物在制备破骨细胞分化抑制剂中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200410 |